Plozasiran, an RNA Interference Agent Targeting APOC3, for …
May 28, 2024 · We carried out a 48-week, phase 2b, double-blind, randomized, placebo-controlled trial evaluating the safety and efficacy of plozasiran, a hepatocyte-targeted APOC3 small interfering RNA, in...
Plozasiran: What is it and is it FDA approved? - Drugs.com
Jan 17, 2025 · Plozasiran is a first-in-class investigational RNA interference (RNAi) therapeutic in development for the treatment of familial chylomicronemia syndrome.
Plozasiran for Managing Persistent Chylomicronemia and …
Sep 2, 2024 · Plozasiran is a small interfering RNA that reduces hepatic production of apolipoprotein C-III and circulating triglycerides. In a phase 3 trial, we randomly assigned 75 patients with...
FDA Accepts Plozasiran NDA for Familial Chylomicronemia …
Jan 20, 2025 · Plozasiran achieved durable reductions in triglyceride levels with an 80% median change from baseline in the 25 mg dose cohort. Key secondary endpoint analysis revealed a statistically significant 83% reduction in the risk of acute pancreatitis with plozasiran, compared with placebo, in the pooled 25 mg and 50 mg cohorts. 3
Arrowhead Pharmaceuticals Presents New Data at AHA24 from …
Nov 16, 2024 · Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced new results from the Phase 3 PALISADE study and the open-label extension from the Phase 2 MUIR and SHASTA-2 studies of investigational plozasiran.
•Plozasiran, an investigational RNAi agent targeting APOC3 mRNA in hepatocytes, demonstrated large reductions in circulating APOC3, TGs, TRL- RC with a good safety profile in placebo-controlled trials
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy …
Plozasiran, previously called ARO-APOC3, is a first-in-class investigational RNA interference (RNAi) therapeutic designed to reduce production of apolipoprotein C-III (APOC3) which is a component of triglyceride rich lipoproteins (TRLs) and a key regulator of triglyceride metabolism.
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The
Jul 1, 2024 · Objective: To determine the tolerability, efficacy, and dose of plozasiran, an APOC3-targeted small interfering-RNA (siRNA) drug, for lowering triglyceride and apolipoprotein C3 (APOC3, regulator of triglyceride metabolism) levels and evaluate its effects on other lipid parameters in patients with sHTG.
Plozasiran, an RNA Interference Agent Targeting APOC3, for …
Sep 12, 2024 · In this randomized, controlled trial involving participants with mixed hyperlipidemia, plozasiran, as compared with placebo, significantly reduced triglyceride levels at 24 weeks. A clinical outcomes trial is warranted.
Arrowhead Pharmaceuticals Announces Acceptance of New Drug …
Jan 17, 2025 · In PALISADE, plozasiran achieved deep and durable reductions in triglycerides with a median change from baseline of 80% in the plozasiran 25 mg group and a statistically significant 83% reduction ...